Cardinal Looks Ahead To A New Decade For US Biosimilars
Cardinal Health’s Dracey Poore Talks Uptake, Interchangeability And Education
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
